Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00887926 · ClinicalTrials.gov registry record · Phase 1
Study of IMC-EB10 in Participant With Leukemia
A Phase 1 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT00887926 is a Phase 1 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 25 participants.
The verdict
NCT00887926, a Phase 1 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if IMC-EB10 is safe for participants with leukemia, and also to determine the best dose of IMC-EB10 to give to participants.
Interventions
- BIOLOGICAL IMC-EB10
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2009-06 |
| Est. Completion | 2010-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00887926
The ClinicalTrials.gov registry entry for NCT00887926 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IMC-EB10 is the first listed.
NCT00887926 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00887926 about?
NCT00887926 is a clinical study titled "Study of IMC-EB10 in Participant With Leukemia". The purpose of this study is to determine if IMC-EB10 is safe for participants with leukemia, and also to determine the best dose of IMC-EB10 to give to participants.
What is the current status of trial NCT00887926?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2009-06. Estimated completion is 2010-08.
What interventions are being tested in trial NCT00887926?
The interventions under investigation include: IMC-EB10 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00887926?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.